Erada Technology Alliance

What Erada Technology Alliance does

ERADA Technology Alliance Ltd. is a Mauritius-incorporated healthtech startup founded in 2018 that develops rapid diagnostic solutions for the early detection of infectious diseases, with an explicit mission focus on eradicating disease in developing-world markets. The company is co-founded by Dr. Benjamin Pretorius (managing director) and Richard Schmidt (director of clinical development), and operates a cross-border footprint with a registered office in Cybercity, Ebene, Mauritius and a South African contact number. The core technology is positioned as innovative rapid diagnostics designed for early detection of infectious diseases in resource-limited settings, targeting public health ministries, national malaria control programs, NGOs, and humanitarian health organizations operating in low- and middle-income countries.

The business model is sales-led and contact-driven: the company's primary public asset is a website directing prospective institutional and government buyers to a contact form rather than offering self-serve purchasing or transparent pricing. Revenue mechanics are not publicly disclosed but are inferred to depend on sale or licensing of diagnostic products to public health buyers in developing-world geographies. The go-to-market motion is direct inside-sales outreach to enterprise and government accounts, with no evidence of channel partnerships, digital marketing, or consumer distribution. The company has raised approximately $316,015 in a single funding round in September 2019 led by De Beers Group, and has not disclosed any subsequent financing, customers, partnerships, patents, regulatory clearances, or commercial deployments in the source material.

Given the absence of disclosed products, pricing, customers, or partnerships, ERADA appears to be at a very early commercialization stage. The operating tagline "Early Detection, Early Treatment - END DISEASE!" and the malaria diagnostics market growing at an estimated 6% CAGR (2021–2026) indicate a market tailwind, but the lack of publicly verifiable traction signals — combined with no further funding rounds disclosed since 2019 — suggests limited commercial scale to date.

Name

Erada Technology Alliance

Legal name

ERADA Technology Alliance Ltd.

Website

https://eradatechnology.com

Company type

Private

Founded year

2018

Headcount range

11–50 employees

Short description

Erada Technology Alliance is a Mauritius-based healthtech startup developing rapid diagnostic solutions for early detection of infectious diseases in developing-world markets, targeting public health ministries, malaria control programs, and NGOs through a direct sales motion.

Ownership category

akta.pro rank

Product category

Infectious Disease Diagnostics

NAICS

Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Infectious Disease Telemedicine Platforms (HLALAGAJ)

akta.pro secondary industry

Syndromic Surveillance & Early Warning Systems (HLAJABAB)

Keywords

• Infectious disease diagnostics
• Rapid diagnostic tests
• Malaria diagnostics
• Public health diagnostics
• Developing world health

Headquarters

HQ city

Ebène

HQ country

Mauritius

HQ region

Africa

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Diagnostic product sales (implied): The company positions itself as a provider of innovative rapid diagnostic solutions for infectious disease detection. Revenue mechanics are not explicitly disclosed in the source material; the model is inferred to be based on sale or licensing of diagnostic products to public health institutions in the developing world.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

ERADA Technology Alliance pioneers innovative rapid diagnostic solutions for the early detection of infectious diseases, targeted at developing world settings where laboratory infrastructure is limited. The company's offering is a single-purpose diagnostic venture focused on enabling early detection and early treatment to end endemic disease burden in low- and middle-income countries.

Product overview

Erada Technology Alliance positions itself as a single-purpose diagnostic venture rather than a multi-module platform: per its website, it is a pioneer of "innovative, rapid diagnostic solutions for early detection of infectious diseases," with the operating tagline "Early Detection, Early Treatment - END DISEASE!" No individually branded products, modules, or sub-products are named in the available source material.

Differentiator

Problem solved

Functional benefit

Products and services

• Rapid Diagnostic Solutions for Infectious Disease Early Detection Innovative rapid diagnostic solutions designed for early detection of infectious diseases, intended for use by governments, NGOs, and public health institutions in developing world and low-resource settings where conventional laboratory infrastructure is unavailable.

Quantifiable outcome

• Malaria diagnostics market growing at 6% CAGR (2021–2026) - contextual market tailwind

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves3 records

Direct peers

• Mologic: UK-based developer of rapid diagnostic tests focused on global health and LMIC use cases (including malaria and neglected tropical diseases). Closely aligned with ERADA on mission, product format (lateral-flow rapid diagnostics), and institutional/NGO buyer base.
• Global Access Diagnostics (GADx): Rapid diagnostic test manufacturer spun out of Mologic specifically to serve LMIC markets at affordable price points. Direct peer on product category, target buyer (governments, NGOs), and value-based pricing model.
• Premier Medical Corporation: India-based manufacturer of rapid diagnostic test kits including malaria RDTs, serving public health and institutional buyers in developing markets. Comparable on product format and target geography.

Broad incumbents

• Abbott (Diagnostics): Operates the Bioline rapid diagnostics portfolio covering malaria, HIV, hepatitis, and other infectious diseases, widely used in LMICs. Competes in the same buyer RFPs as ERADA but as part of a global diversified diagnostics business with WHO PQ approvals.
• SD Biosensor: Major South Korean rapid diagnostic test manufacturer with extensive malaria and infectious disease RDT lines distributed globally, including WHO PQ-approved products for LMIC procurement.
• Access Bio: US/Korean-headquartered manufacturer of rapid diagnostic tests for malaria and other infectious diseases with strong presence in African public health procurement channels.
• Arkray: Japanese diagnostic device and reagent company with malaria and infectious disease test products. Broad incumbent with overlapping product categories in institutional channels.

Emerging players

• QuantuMDx: Developer of molecular and rapid diagnostic devices intended for low-resource and field settings, including infectious disease targets. Comparable on LMIC-focused point-of-care diagnostic thesis.
• Noul (miLab): Developer of AI-augmented blood-cell and infectious disease diagnostic platforms for resource-limited settings. Comparable on technology-forward diagnostic approach to LMIC use cases.

Regional players

• Span Diagnostics: Indian in-vitro diagnostics manufacturer producing rapid test kits including infectious disease panels for emerging markets. Adjacent regional peer serving similar institutional buyers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Erada Technology Alliance